Cassava Sciences: Is The Market Still Buying Simufilam? (NASDAQ:SAVA)

Sad, tired and depressed doctor with mental health problem from working at hospital, thinking of idea with depression and doubt about medical surgery. Healthcare nurse with anxiety and arms crossed

Moyo Studio/E+ via Getty Images

Investment Overview

Cassava Sciences (NASDAQ:SAVA) stock has endured a difficult 2023 to date – falling in value from ~$28 at the start of the year, to ~$17 at the beginning of this week, down nearly 40% – but yesterday brought some light

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *